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Changes in human behavior and lifestyle have resulted in a dramatic increase of diabetes 
mellitus (DM) worldwide. In the Netherlands alone, the number of people with type 2 
DM is rapidly increasing with an estimated prevalence of 1.2 million people. Up to 50% 
of the patients with DM develop diabetic peripheral neuropathy (DPN). However, not 
all patients with diabetes will develop a painful DPN (PDPN). PDPN is associated with 
high pain scores, and may cause physical and emotional suffering with severe impact on 
Quality of Life (QoL) and resulting cost-of-illness. This trend is alarming, and it demands 
policy measures on the part of the government and health care sector and the search 
for effective and cost-effective treatment modalities for this specific group of people. As 
the current pharmacological treatment often is only partially effective or unsuccessful 
due to unacceptable side-effects further research into the pathophysiology of PDPN is 
necessary. This knowledge can help to improve and develop new treatment modalities 
for PDPN. Spinal cord stimulation (SCS) is considered a possible last resort treatment 
modality to treat patients who do not experience sufficient pain relief due to pharmaco-
logical treatment.          
 In this thesis, we have shown that pain coverage of both lower extremities can 
be achieved with the use of only one Octlead, that it is safe and an effective intervention 
in pain reduction in PDPN. The favorable results of the pilot study justified performing a 
larger randomized clinical trial (RCT). In a multi-center randomized clinical trial we have 
shown that conventional SCS has a short- and long-term treatment effect on pain and 
Quality of Life (QoL) in PDPN patients and is accompanied with limited side effects. As 
shown in a recent publication by the departmental research team, 55% of the patients 
had a treatment success after 5 years and 80% of the patients with PDPN still use their 
device after 5 years of treatment. Our secondary analysis in the cost-effectiveness study 
indicated that SCS is likely to become cost-effective within 4 years, but nevertheless, SCS 
requires a substantial initial investment and follow-up of patients. Furthermore, there is 
also a group of patients that does not respond well to SCS or experiences a reduction in 
treatment effect over time. Continuing the search for the underlying pathophysiologic 
mechanism of PDPN and the underlying mechanism of long-term SCS can optimize 
SCS in PDPN. In addition, it would be favorable in predicting long-term success in PDPN 
patients due to SCS. In our study we implemented the Michigan Diabetic Neuropathy 
Score (MDNS) in the screening of the PDPN patients. However, no differences in MDNS 
scores in the patients with a negative trial stimulation were observed. It is conceivable 
that the MDNS is not an adequate predictive tool, as it is a composite measure, and 
therefore it would be difficult to discriminate between the different factors included in 
this score. In contrast to our study, a recent publication of the departmental research 
team, combining the patients of the pilot- and RTC study, showed that the severity of 
the neuropathy is associated with a higher chance of long-term treatment failure during 
5 years follow-up. Not just the search for a SCS outcome predictor, but also the search for 11
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optimal stimulation parameters (frequency, waveform and polarity) is an option, includ-
ing high frequency (HF) stimulation, burst stimulation and Dorsal Root Ganglion (DRG) 
stimulation. However, the working mechanisms of HF- and burst stimulation are still a 
topic of debate and further research is needed to optimize the stimulation settings for 
PDPN patients, and thereby for all neuropathic pain patients, and should be investigated 
in a randomized clinical trial. In addition, technology of neurostimulators is developing 
rapidly, delivering a large set of parameter combinations, and rechargeable batteries are 
available, but are quite expensive and costs are not always covered by health insurance. 
Continued research is needed on long-term SCS in PDPN to further reveal the work-
ing mechanism of the different SCS modalities, to identify predictive factors for treat-
ment success and to improve overall success rate of SCS. Reduction in medication in-
take due to SCS is also visible in PDPN patients, which reduces health care costs and in 
addition has a positive effect on patients QoL due to less/no side effects of medication. 
 Nevertheless, the short-term treatment (12 months) is not cost-effective due 
to the high substantial initial investment of SCS. Continued follow-up of the implant-
ed PDPN patients is necessary to demonstrate the long-term effect on pain and com-
plications of SCS treatment in PDPN patients, and in addition the economic burden 
of PDPN. A thorough decision analytic model can provide better insight in the long-
term cost-effectiveness of SCS in this patient group, including the long-term effect 
on pain, health care costs, life expectancy, longevity of the SCS material, and com-
plication- and implantation rate of SCS. In addition, predictors for SCS treatment out-
come may also lead to an increase of the cost effectiveness of SCS.    
 With the increasing number of potential PDPN patients, the implementation of 
SCS as possible treatment modality for PDPN should get a boost. Hopefully, the published 
literature and long-term follow-up studies on SCS in PDPN can contribute to a positive im-
plementation of this treatment modality. A positive step has been taken to implement SCS 
for PDPN in the Dutch Pain Guidelines for the Dutch Association for Anesthesiology, sec-
tion Pain medicine and the Flemish Association for Anesthesiology for Pain Medicine. Add-
ing SCS for PDPN in the guidelines together with a long-term study on effectiveness and 
cost-effectiveness may improve further implementation of SCS as a therapeutic option, 
improve the treatment of patients with invalidating pain, and thereby reduce the subjec-
tive and economic burden of PDPN.   
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